Biosimilars

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

Biocon shares climbed 6.5 per cent after reports of Viatris unit Mylan's planned stake sale, with analysts saying the move is a financial decision that removes a long-standing overhang

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

From India's FTA strategy and Sun Pharma's global ambitions to LPG shortages, West Asia risks and Asean ties, here are the key insights from today's Opinion page

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

The product, a biosimilar to Amgen's popular drug Neulasta, will be manufactured at Lupin's biotech facility in Pune

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the way for commercialisation of two biosimilars used in the treatment of osteoporosis and cancer-related bone conditions. Biocon Biologics has inked the pact with Amgen Inc for the commercialisation of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the US, the company said in a regulatory filing. Bosaya 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial are biosimilars to Amgen's Prolia and Xgeva, respectively. These products are used in the treatment of osteoporosis and cancer-related bone conditions. Biocon Biologics and Amgen executed the settlement agreement to resolve the pending patent litigation at the US District Court for the District of New Jersey, the Bengaluru-based firm said. The agreement enables Biocon Biologics to launch Bosaya and Aukels

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Biocon Biologics bought Viatris' global biosimilars business last year to become one of the top five global players in the space

Cipla stock went up by almost 3 per cent on Tuesday

Biocon Biologics is an arm of biotechnology major Biocon

Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"

Ramp-up and new biosimilars should help boost profit

The company is uniquely positioned in the US as it is the only Indian pharmaceutical firm with two commercialised biosimilars in the market

Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled